‘Increased survival rates’ for bladder cancer patients given immunotherapy drug

The Royal Hallamshire Hospital. Credit: Getty/LizzieMaher

By Jane Kirby, PA Media

Bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive, according to a study.

Patients with advanced (muscle-invasive) bladder cancer had significantly less risk of cancer progressing or returning when treated with durvalumab, and were more likely to still be alive 2 years after treatment.